<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Therapeutic serum concentration monitoring of antituberculous drugs in adults</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Therapeutic serum concentration monitoring of antituberculous drugs in adults</h1>
<div class="graphic"><div class="figure"><div class="ttl">Therapeutic serum concentration monitoring of antituberculous drugs in adults</div><div class="cntnt"><table cellspacing="0"><colgroup width="13%"></colgroup> <colgroup span="3" width="29%"></colgroup> <tbody> <tr> <td class="subtitle1">Drug name</td> <td class="subtitle1">Timing for collection of serum concentration</td> <td class="subtitle1">Target peak concentration</td> <td class="subtitle1">Time for additional sampling<br/> to assess for delayed absorption or malabsorption of orally administered drug*</td> </tr> <tr> <td>Amikacin</td> <td> <p>Intramuscular: 2 and 6 hours</p> Intravenous: 2 and 6 hours after completion of a 30 to 60 minute <span class="nowrap_whitespace">infusion<sup>¶</sup></span></td> <td>Target for calculated peak <span class="nowrap_whitespace">concentration:<sup>¶</sup></span> <ul class="decimal_heading"> <li>35 to 45 mcg/mL (for 15 mg/kg once daily dose)</li> <li>65 to 80 mcg/mL (for 25 mg/kg twice weekly dose)</li> </ul> </td> <td>Not applicable</td> </tr> <tr> <td><span class="nowrap_whitespace">Capreomycin<sup>Δ</sup></span></td> <td> <p>Intramuscular: 2 and 6 hours</p> Intravenous: 2 and 6 hours after completion of a 30 to 60 minute <span class="nowrap_whitespace">infusion<sup>¶</sup></span></td> <td>Target for calculated peak <span class="nowrap_whitespace">concentration:<sup>¶</sup></span> <ul class="decimal_heading"> <li>35 to 45 mcg/mL (for 15 mg/kg daily dose)</li> <li>65 to 80 mcg/mL (for 25 mg/kg twice weekly dose)</li> </ul> </td> <td>Not applicable</td> </tr> <tr> <td>Clofazimine</td> <td>Oral: 2 to 3 hours (fasting), 4 to 8 hours (when given with food)</td> <td>0.5 to 2 mcg/mL</td> <td>6 to 7 hours (fasting only)</td> </tr> <tr> <td>Cycloserine</td> <td>Oral: 2 hours</td> <td>20 to <span class="nowrap_whitespace">35 mcg/mL<sup>◊</sup></span></td> <td>6 hours</td> </tr> <tr> <td>Ethambutol</td> <td>Oral: 2 to 3 hours</td> <td> <p>2 to 6 mcg/mL (for 15 to 25 mg/kg daily dose)</p> 4 to 12 mcg/mL (for 50 mg/kg thrice or twice weekly dose)</td> <td> <p>6 to 7 hours</p> Delayed or erratic absorption occurs frequently</td> </tr> <tr> <td>Ethionamide</td> <td>Oral: 2 hours</td> <td>1 to 5 mcg/mL</td> <td> <p>6 hours</p> Delayed or erratic absorption occurs frequently</td> </tr> <tr> <td>Isoniazid</td> <td>Oral: 2 hours (fasting); some also check 6-hour levels</td> <td> <p>3 to 5 mcg/mL (for 5 mg/kg up to 300 mg daily dose)</p> 9 to 15 mcg/mL (for 15 to 25 mg/kg twice weekly dose)</td> <td>6 hours</td> </tr> <tr> <td>Kanamycin</td> <td> <p>Intramuscular: 2 and 6 hours</p> Intravenous: 2 and 6 hours after completion of a 30 to 60 minute <span class="nowrap_whitespace">infusion<sup>¶</sup></span></td> <td>Target for calculated peak <span class="nowrap_whitespace">concentration:<sup>¶</sup></span> <ul class="decimal_heading"> <li>35 to 45 mcg/mL (for 15 mg/kg daily dose)</li> <li>65 to 80 mcg/mL (for 25 mg/kg twice weekly dose)</li> </ul> </td> <td>Not applicable</td> </tr> <tr> <td>Levofloxacin</td> <td>Oral: 2 hours</td> <td>8 to 12 mcg/mL</td> <td>6 hours</td> </tr> <tr> <td>Linezolid</td> <td> <p>Oral: 2 hours</p> Intravenous: 30 minutes after completion of infusion</td> <td>12 to 24 mcg/mL</td> <td>Not generally performed</td> </tr> <tr> <td>Moxifloxacin</td> <td>Oral: 2 hours*</td> <td>3 to 5 mcg/mL</td> <td>6 hours</td> </tr> <tr> <td>Para-aminosalicylic acid</td> <td>Oral: 6 hours (enteric-coated sustained release PASER formulation)</td> <td>20 to 60 mcg/mL</td> <td>Not applicable</td> </tr> <tr> <td>Pyrazinamide<sup>§</sup></td> <td>Oral: 2 hours</td> <td> <p>20 to 40 mcg/mL (for 25 mg/kg daily dose)</p> 60 to 80 mcg/mL (for 50 mg/kg thrice or twice weekly dose)</td> <td>6 hours</td> </tr> <tr> <td>Rifabutin<sup>¥</sup></td> <td>Oral: 3 hours</td> <td>0.45 to 0.9 mcg/mL</td> <td>7 hours</td> </tr> <tr> <td>Rifampin (rifampicin)</td> <td>Oral: 2 hours</td> <td>8 to 24 mcg/mL</td> <td> <p>6 hours</p> We routinely perform 6-hour levels in <strong>all</strong> patients receiving rifampin to assess for delayed absorption or malabsorption*</td> </tr> <tr> <td>Streptomycin</td> <td> <p>Intramuscular: 2 and 6 hours</p> Intravenous: 2 and 6 hours after completion of a 30 to 60 minute <span class="nowrap_whitespace">infusion<sup>¶</sup></span></td> <td>Target for calculated peak <span class="nowrap_whitespace">concentration:<sup>¶</sup></span> <ul class="decimal_heading"> <li>35 to 45 mcg/mL (for 15 mg/kg daily dose)</li> <li>65 to 80 mcg/mL (for 25 mg/kg twice weekly dose)</li> </ul> </td> <td>Not applicable</td> </tr> </tbody></table></div><div class="graphic_lgnd">Therapeutic drug monitoring (TDM) is warranted for the injectable antituberculous agents (amikacin, streptomycin, kanamycin, and capreomycin), especially in patients with renal impairment, and for oral antituberculous agents when needed to assess for delayed or malabsorption. For specific recommendations on other clinical situations in which drug concentration monitoring should be pursued, refer to the accompanying UpToDate text. Serum concentration monitoring should be performed after the patient has received therapy for three to five half-lives of the drug, typically after two or three maintenance doses at a fixed-dose interval.</div><div class="graphic_footnotes"><p>* To assess for delayed or malabsorption, a second sample should be collected approximately 6 to 7 hours after an oral dose (depending on the drug as noted above). This is particularly important for patients with a history of diabetes mellitus, gastrointestinal disorders, HIV, cystic fibrosis, or alcohol abuse and in all patients receiving ethambutol or ethionamide. In delayed absorption, the 6- or 7-hour concentration is similar to or higher than 2-hour values. If both values are beneath the expected peak, malabsorption should be suspected.</p>
<p>¶ Serum concentrations of aminoglycosides (amikacin, streptomycin, kanamycin) and capreomycin obtained less than 2 hours after an intramuscular dose or completion of an intravenous infusion may be falsely elevated due to incomplete distribution of drug to body tissues. To avoid misinterpretation, two post-distribution concentrations should be drawn and the peak concentration determined by pharmacokinetic calculation using linear regression to 1 hour post-intramuscular dose or end of intravenous infusion. These calculations are usually performed by pharmacists skilled in aminoglycoside clinical pharmacokinetics. Trough concentrations (target &lt;5 mcg/mL to undetectable) may also be evaluated to confirm drug clearance following a 24-hour dose. Refer to the UpToDate topic review of aminoglycosides dosing and administration for detail.</p>
<p>Δ Capreomycin is not available in the United States; availability in other countries is limited.</p>
<p>◊ Central nervous system toxicity is associated with cycloserine concentrations &gt;35 mcg/mL but may occur at even lower concentrations. Some experts prefer to maintain the concentration &lt;30 mcg/mL.</p>
<p>§ An elevated uric acid is an expected additional finding in patients on pyrazinamide. If not present, it may indicate that the patient is not taking the drug or there is malabsorption.</p>
    
    ¥ Rifabutin is absorbed more slowly than most other oral agents. On the day of sampling only, rifabutin can be given 1 hour before the other drugs, so that rifabutin sample times match the 2- and 6-hour times for other drugs. This limits the collection to two venipunctures.</div><div class="graphic_reference">References:
    <ol>
<li>Nahid P, Mase SR, Migliori GB, et al. Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. Am J Respir Crit Care Med 2019; 200:e93.</li>
<li>Nahid P, Dorman S, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis 2016; 63:e147.</li>
<li>Alsultan A, Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis: An update. Drugs 2014; 74:839.</li>
<li>Curry International Tuberculosis Center and California Department of Public Health. Drug-Resistant Tuberculosis: A Survival Guide for Clinicians, Third Edition. 2016. Available at http://www.currytbcenter.ucsf.edu/products/cover-pages/drug-resistant-tuberculosis-survival-guide-clinicians-3rd-edition.</li>
</ol></div><div id="graphicVersion">Graphic 109278 Version 4.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
